The filing contains no new clinical data or guidance changes — the stock will trade on binary catalyst expectations for the PRECISE-AD interim analysis in early Q3 2026. Monitor for any safety signals or biomarker trends in the blinded readout, which could provide early directional insight on PMN310's target engagement.
Price Chart
Executive Summary
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs $7.3 million in Q1 2025) and a cash position of $63.8 million following a $75.5 million PIPE financing. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech, with no new clinical data or guidance changes — the key catalyst remains the PRECISE-AD Phase 1b interim analysis expected in early Q3 2026.
Key Financial Metrics
Key Facts
- Net loss of $8.2 million for Q1 2026, compared to $7.3 million in Q1 2025
- Cash and cash equivalents of $63.8 million as of March 31, 2026, up from $6.1 million at year-end 2025
- Closed a PIPE financing in February 2026 for gross up-front proceeds of $75.5 million, with potential additional $100 million from warrant exercises
- PRECISE-AD Phase 1b trial fully enrolled with 144 participants; blinded 6-month interim analysis anticipated in early Q3 2026
- 12-month unblinded top-line data expected in early 2027
- Cash runway expected to fund operations through 2027, including completion of the PRECISE-AD trial
- No revenue reported; company is a pre-revenue clinical-stage biotechnology firm
Financial Impact
Net loss increased 12.2% YoY to $8.2 million; cash position strengthened to $63.8 million post-financing
Risk Factors
- Clinical trial failure risk — PMN310 may fail to show differentiated safety or efficacy in the Phase 1b trial
- Dilution risk — warrants from the February PIPE could add up to $100 million in additional shares if exercised
- No revenue and ongoing operating losses — company is entirely dependent on financing and pipeline progress
- Competitive risk from approved plaque-directed AD therapies with black box warnings for ARIA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-058967 |
| Document: pmn-20260512x8k.htm | 0001104659-26-058967 |
| Document: 0001104659-26-058967-index-headers.html | 0001104659-26-058967 |
| Document: 0001104659-26-058967-index.html | 0001104659-26-058967 |
| Document: 0001104659-26-058967.txt | 0001104659-26-058967 |
| 8-K Data (Synthetic) | 0001104659-26-058967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 3 | $9.12 $9.15 | ▲ +0.33% | ▲ +0.75% | $9.68 (+6.14%) |
Oct 6, 2026 21d ago | Press Release | $9.21 $9.12 | ▼ −0.98% | ▼ −0.74% | $9.68 (+5.10%) |
Sep 1, 2026 8w ago | Press Release | $13.35 $13.98 | ▲ +4.68% | ▲ +4.24% | $9.68 (−27.49%) |
Jul 14, 2026 15w ago | Press Release | $13.66 $14.01 | ▲ +2.53% | ▲ +2.13% | $9.68 (−29.14%) |
May 28, 2026 21w ago | Press Release | $10.87 $10.81 | ▼ −0.55% | ▼ −0.79% | $9.68 (−10.95%) |
May 12, 2026 24w ago | 8-K | $10.49 $10.57 | ▲ +0.76% | ▲ +0.19% | $9.68 (−7.72%) |
Apr 3, 2026 29w ago | EFFECT | $10.96 $10.88 | ▲ +0.73% | ▲ +0.79% | $9.68 (+11.68%) |
Mar 25, 2026 30w ago | S-3 | $15.13 $14.74 | ▲ +2.58% | ▲ +0.90% | $9.68 (+36.02%) |
Mar 18, 2026 31w ago | S-3 | $18.21 $17.60 | ▲ +3.35% | ▲ +1.61% | $9.68 (+46.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers